WO2004037223A2 - Liposomen formende zusammensetzung - Google Patents
Liposomen formende zusammensetzung Download PDFInfo
- Publication number
- WO2004037223A2 WO2004037223A2 PCT/EP2003/011758 EP0311758W WO2004037223A2 WO 2004037223 A2 WO2004037223 A2 WO 2004037223A2 EP 0311758 W EP0311758 W EP 0311758W WO 2004037223 A2 WO2004037223 A2 WO 2004037223A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- lipid
- liposomes
- composition according
- liposome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
Definitions
- the present invention relates to a liposome-forming composition, the use of this composition for the formation of liposomes and liposomes, obtainable through the use of the liposome-forming composition.
- Liposomes are artificially produced uni- or multilamellar lipid vesicles that enclose an aqueous interior. They are generally similar to biological membranes and are therefore often easily integrated into the membrane structure or attached to the cell membrane after attachment to them. In the first case, the contents of the liposome interior are discharged into the lumen enclosed by the biological membrane. In the second case, the liposomal content can be discharged into the space between the cells. For example, this is a possible prerequisite for the paracellular transport of active substances from the intestine into the body through the intestinal wall.
- Liposomes are therefore used as transport vehicles for substances such.
- Mainly natural soybeans or egg yolk lecithins or defined natural or artificial phospholipids such as cardiolipin, sphingomyelin, lysolecithin and others are used to produce liposomes.
- the first liposomes were disadvantageous in that they had little stability. Liposomes formed from normal double-layer-forming phospholipids were only stable for a short time even when cooled. Their storage stability can be increased by including phosphatidic acid, but the stability that has been improved in this way is still insufficient for many purposes. In addition, such conventional liposomes were not acid-stable and were also not sufficiently resistant to digestion in the small intestine and were therefore unsuitable for the transport of active pharmaceutical ingredients which, after oral administration, affected the stomach and the thin pass through the bowel, DNA transfection supported by the liposomes under slightly acidic pH conditions.
- tetraether lipid derivatives such as those that can be obtained from natural sources, for example.
- derivatized tetraether lipid derivatives and synthetic tetraether lipid derivatives For example, reference is made here to the compounds disclosed in German patent applications 197 36 592.2, 197 58 645.7, 100 65 561.0, 102 04 053.2 and 102 29 438.0.
- liposome-forming compositions which allow liposomes to be shaped securely, while at the same time ensuring adequate mechanical and chemical stability and thus an extended shelf life, which enables simple and reliable applicability.
- these liposome-forming compositions should have a suitable variability so that desired property profiles can be set in a targeted and reliable manner.
- liposome-forming compositions according to claim 1. Preferred embodiments are specified in the subclaims.
- the present invention provides liposomes, obtainable through the use of the liposome-forming composition according to the invention.
- the present invention provides the use of the liposome-forming composition to form liposome available. Preferred embodiments of these two embodiments of the present invention are specified in the respective subclaims.
- compositions according to the invention are particularly suitable for shaping liposomal formulations to be administered orally.
- composition according to the invention contains two essential components.
- the liposome-forming composition according to the invention comprises at least one lipid which is capable of forming a double layer.
- lipids are known to the person skilled in the art. Any lipids capable of forming a bilayer may be used in the present invention, which lipids may be derived from a biological source or may be synthetically produced. Preferred in this connection are phospholipids of the following general formula
- R 1 and R 2 represent an aliphatic hydrocarbon chain, an acyl group or a saturated or unsaturated fatty acid residue.
- Preferred in this context are alkyl groups with 10 to 20 carbon atoms, acyl groups with 10 to 20 carbon atoms and an oleoyl group, a palmitoleloyl group, an elaidoyl group, a linoleyl group, linolenyl group, a linolenoyl group, an arachidoyl group, a vaccinyl group, a lauroyl group, a myristoyl group, a palmitoyl group or a stearoyl group.
- R 3 is preferably hydrogen, 2-trimenthylamino-1-ethyl, 2-amino-1-ethyl, C1-C4-alkyl, C1-C5-alkyl, substituted with a carboxy group, C2-C5-alkyl, substituted with a hydroxyl group, C2-C5-alkyl substituted with a carboxyl group or a hydroxyl group or C2-C5-alkyl substituted with a carboxyl group and an armino group, inositol, sphingosine or salts of said substances.
- Glycerides isoprenoid liquids, steroids, sterols or sterols of sulfur-containing or carbohydrate-containing lipids or any other double-layer-forming lipids, in particular their semi-protonated fluid fatty acids and the like.
- Other lipids that can be used are phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phosphatidylinositols, phosphatidic acids, phosphatidylserines, sphingomyelins and other sphinophospholipids, glycosphingolipids, gangliosides and other glycolipids or synthetic lipids.
- lipid capable of forming a double layer there must be at least one such lipid capable of forming a double layer.
- two or more such lipids in the composition according to the invention can ensure, for example, secure attachment to the desired destination or secure storage of a pharmaceutical agent to be introduced into the liposome.
- Particularly preferred double-layer-forming lipids are 1,2-di-stearoyl-sn-glycero-3-phosphocholine (hereinafter abbreviated DSPC, formula given below)
- soy phosphatidylcholine S-PC, brand names: S100, S80 from LIPOID
- egg phosphatidylcholine egg PC
- HSPC hydrogenated soy phosphatidylcholine
- HEPC hydrogenated egg phosphatidylcholine
- the second essential component of the composition according to the invention is a tetraether lipid which spans the double layer formed by the lipids used according to the invention.
- any tetraetheriipid can be used which is suitable for replacing a pair of the lipid-forming lipids in the bilayer formed by the lipids described.
- Preferred tetraether lipids are in particular those mentioned in WO 99/10337.
- the tetraether lipids can also be used, which are disclosed in the German patent applications mentioned above.
- Preferred tetraether lipids are those of the following formula (1):
- S 1 and S 2 may be the same or different and each has the following meaning:
- Y can mean -NR R 3 or -N ⁇ R 4 "R
- X 1 and X 2 may be the same or different and are each independently selected from the group comprising a branched or unbranched alkylene or alkenylene having 2 to 20 carbon atoms;
- R 1 to R 6 may be the same or different and are each independently selected from the group comprising: hydrogen, branched or unbranched alkyl, alkenyl, aralkyl or aryl groups having 1 to 12 carbon atoms, one of the radicals R 2 to R 6 may further comprise an antibody against cell surface molecules or a ligand for cell surface receptors; and
- n can be an integer between 0 and 10,
- the substituents S 1 and S 2 are the same at both ends of the tetraether lipid backbone. Based on natural tetraether lipids, this enables synthesis without the interim use of protective groups.
- the identity of the substituents S 1 and S 2 is particularly preferred in those cases in which none of the radicals R 1 to R 6 is an antibody or ligand for a cell surface receptor.
- the group X 1 in both S 1 and S 2 is an alkylene or alkenylene having 2 to 10, preferably 3 to 6, carbon atoms. In very particularly preferred embodiments, X 1 is propylene.
- the group X 2 is also preferably an alkylene or alkenylene with 2 to 10, preferably with 3 to 6, carbon atoms. Propylene radicals are also particularly preferred for X 2 .
- n can mean 0 to 10. In preferred embodiments, n is 0 to 3, very particularly preferably 0.
- Y denotes both in S 1 and in S 2 -NR 2 R 3 .
- R 2 and R 3 are preferably hydrogen, branched or unbranched alkyl, alkenyl, aralkyl or aryl groups, particularly preferably hydrogen, methyl, ethyl or propyl groups.
- Y means both in S 1 and in S 2 a quaternary ammonium salt, the radicals R 4 , R 5 and R 6 of which are likewise preferably hydrogen, branched or unbranched alkyl, alkenyl, aralkyl or aryl groups having 1 to 12 carbon atoms, are particularly preferably hydrogen, methyl, ethyl or propyl.
- R 2 to R 6 may comprise an antibody against cell surface molecules or a ligand for cell surface receptors.
- the tetraether lipid derivative according to the invention has the general formula (I) with the substituents S 1 and S 2 given below:
- the presence of at least one tetraetheriipid is mandatory according to the invention.
- mixtures of different tetraether lipids can also be used here.
- the property profile of the liposomes formed from the composition according to the invention can be set in a targeted manner by suitable selection of the head groups, as already described above in connection with the double-layer-forming lipids.
- GCTE glycerol calditol tetraether lipid
- open-chain tetraether lipids are those that are mentioned in German applications 102 04 053.2 and 102 29 438.0, which are fully encompassed here by this reference, the following compound being particularly preferred:
- a tetraetheriipid which is particularly preferably used in combination with GCTE, is a tetraetheriipid with cationic head groups, preference being given to the compound AF1, the formula of which is shown below.
- composition according to the invention can contain any mixing ratios of bilayer-forming lipids and tetraether lipids, it has been shown that it is preferred if the molar ratio of bilayer-forming lipid to tetraetheriipid is in the range from 1: 5 to 10: 1, more preferably in the range from 2.5: 1 to 5: 1 and most preferably in the range 2.5: 1 to 3.5: 1.
- a tetraetheriipid as defined above with cationic head groups such as AF1
- a molar ratio of double-layer-forming lipid: tetraetheriipid: tetraetheriipid with cationic head groups 10 to 4) :( 2 to 1) :( 1 to 0.2)
- a ratio of 6: 1, 5: 0.5 being particularly preferred.
- a particularly preferred combination according to the invention is either a composition of DSPC and GCTE, with a molar ratio DSPOGCTE of 3: 1 or a composition of DSPC and GCTE and AF1, with a molar ratio DSPC: GCTE: AF1 of 6: 1.5: 0.5.
- the liposome-forming composition according to the invention can contain, in addition to the essential components described above, additional components. These are described below.
- composition according to the invention can also comprise at least one preservative, preferably a microbicide.
- a microbicide preferably selected from short-chain alcohols, preferably ethyl alcohol and isopropyl alcohol, chlorobutanol, benzyl alcohol, chlorobenzyl alcohol, dichlorobenzyl alcohol, hexachlorophene, phenolic compounds such as cresol, 4-chloro-m-cresol, p-chloro-m-xylenol, dichlorophen, hexachlorophen , Providone iodide, parabens, in particular alkyl parabens, such as methyl, ethyl, propyl or butyl paraben, benzyl paraben, acids, such as sorbic acid, benzoic acid and their salts, quaternary ammonium compounds, such as aluminum salts, for.
- short-chain alcohols preferably ethyl alcohol and isopropyl alcohol,
- mercury compounds such as phenylmercury acetate, bo
- This compound is preferably added in an amount such that it reduces the amount of bacteria in accordance with the following rule: reducing the amount of bacteria by adding 1,000,000 germs per gram of the total mass of the composition to less than 100, in the case of aerobic bacteria, or less than 10, in the case of entero-bacteria, and less than 1, in the case of Pseudomonas aeruginosa or Staphilococus aureus, after 4 days.
- this compound is preferably added in an amount so that this reduction is achieved after 3 days and most preferably after one day.
- Short-chain alcohols preferably ethyl alcohol, propyl alcohol, butyl alcohol or benzyl alcohol: up to 10% by weight, more preferably up to 5% by weight and most preferably in the range between 0.5 and 3% by weight, based on the Overall composition, a range from 0.3 to 0.6% by weight being particularly preferred for chlorobutanol;
- Parabens in particular methylparaben: 0.05 to 0.2% by weight, based on the total composition, and for propylparaben particularly preferably 0.002 to 0.02% by weight;
- Sorbic acid 0.05 to 0.2% by weight, benzoic acid, 0.1 to 0.5% by weight;
- Phenols, trichlosan 0.1 to 0.3% by weight
- Chlorhexidine 0.01 to 0.05% by weight, based on the total composition.
- Another additional component of the composition according to the invention can be an antioxidant. Any antioxidant which is compatible with the essential components of the composition according to the invention can be used according to the invention.
- the at least one antioxidant is preferably used in an amount which reduces the oxidation index to less than 100% per 6 months, preferably the increase in the oxidation index is reduced to less than 100% per 12 months and particularly preferably to less than 50% per 12 months.
- the antioxidant used according to the invention can be selected from the following group:
- Synthetic phenolic antioxidants such as butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT) and di-t-butylphenol (LY178002, LY256548, HWA-131, BF-389, CE-986, PD-127443, E-5119, BI -L-239XX), tertiary butylhydroquinone (TBHQ), propylgaleate (PG), 1-O-hexyl-2,3,5-trimethylhydroquinone (HTHQ), aromatic amines (diphenylamine, p-alkylthio-o-anisidine, ethylenediamine derivatives, carbazole , Tetrahydroindenoindole), phenols and phenolic acids (guaiacol, hydroquinone, vanillin, gallic acids and their esters, protocatechuic acid, quinic acid, syringic acid, ellagic acid, salicylic acid, nordihydro
- 6-o-lauroyl- Myristoyl-, palmitoyl-, oleyl- or linoleoyl-L-ascorbic acid etc.
- non-steroidal anti-inflammatory agents such as indomethacin, diclotenac, metenamic acid, flutenamic acid, phenylbutazone, oxyphenbutazone, acetylsalicyl, acetylsalicyl Ibuprofe ⁇ , ketoprofen, piroxicam, penicilamine, penicilamine disulphide, primaquine, quinacrine, chloroquine, hydroxychloroquine, acatioprin, phenobarbital, acetaminophen), amino-licylic acids and derivatives; Methotrexate, probucol, antiarrhythmic agents, (amiodarone, apridine, asocainol), ambroxol, tamoxifen, b-hydroxy
- cloves from cloves, cinnamon, sage, rosemary, mace, oregano, clove pepper, nutmeg); Carnosic acid, camosol, carsolic acid; Rosemary acid, rosamridiphenol, gentisic acid, ferulinic acid; Oatmeal extracts, such as avenathramide 1 and 2, thioethers, dithioethers, sulfoxides, tetraalcylthiuram disulfides; Phytic acid, steroid derivatives (e.g. U74006F); Tryptophan metabolites (e.g. 3-hydroxykynurenine, 3-hydroxyanthranilic acid); and organochalcogenides.
- Carnosic acid, camosol carsolic acid
- Rosemary acid rosamridiphenol, gentisic acid, ferulinic acid
- Oatmeal extracts such as avenathramide 1 and 2, thioethers, dithioethers, sul
- This concentration for BHA or BHT is from 0.001 to 2% by weight, more preferably between 0.025 and 0.2% by weight and most preferably between 0.005 and 0.02% by weight, in each case based on the total composition, for TBHQ and PG between 0.01 and 2% by weight, more preferably between 0.005 and 0.2% by weight and most preferably between 0.01 and 0.02% by weight, for the tocopherols between 0.005 and 5% by weight %, more preferably between 0.01 and 0.5% by weight and most preferably between 0.05 and 0.075% by weight, for ascorbic acid esters between 0.001 and 5% by weight, more preferably between 0.005 and 0.5 wt% and most preferably between 0.01 and 0.15 wt%, for ascorbic acid between 0.001 and 5 wt%, more preferably between 0.005 and 0.5
- a consistency generator is a compound that can influence the swelling rate of the composition according to the invention.
- Consistency generators are preferably used in the composition according to the invention which increase the swelling rate from the dry state to the state of complete solvation by at least a factor of 10.
- Such consistency agents include, in particular, pharmaceutically acceptable hydrophilic polymers, such as partially etherified cellulose derivatives, including caboxymethyl cellulose, hydoxyethyl cellulose, hydoxypropyl cellulose, hydoxypropyl methyl cellulose, hydoxymethyl cellulose or methyl cellulose, completely synthetic hydrophilic polymers, including polyacrylates, polymethacrylates, polyethyl methacrylate, poly methoxy acrylate, poly methoxy acrylate , Polyhydoxypropylmethylacrylate, polyacrylonitrile, le Methallysulfonat, polyethylenes, polyoxyethylenes, Polyethylenclycole, Polyethylenglycollactid, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohols, Polypropylmethacrylamid, Polypropylentumarat-co-Ethylenclycol, polyoxamers
- These consistency agents can be used individually or in a mixture and are preferably used in an amount of 0.05 to 10% by weight, based on the total composition, more preferably 0.1 to 5% by weight, more preferably 0.25 to 3.5% by weight and most preferably in the range of 0.5 to 2% by weight.
- composition according to the invention can also contain additional additives, such as cryoprotectants, Selective aids, swelling aids, stabilizers, dyes etc. as long as these substances do not adversely affect the composition according to the invention.
- additional additives such as cryoprotectants, Selective aids, swelling aids, stabilizers, dyes etc.
- composition according to the invention described above is suitable for shaping liposomes.
- These can be shaped, for example, by suspending the composition according to the invention in a physiologically acceptable buffer, such as a phosphate buffer, a citrate buffer, an acetate buffer or the like.
- a physiologically acceptable buffer such as a phosphate buffer, a citrate buffer, an acetate buffer or the like.
- the molarity of the buffer is in the range from 10 mM to 1,000 mM
- the pH is preferably in the range between 2 and 9 and more preferably in the range between 3 and 6.
- the necessary process steps for the formation of liposomes are known to the person skilled in the art.
- liposomes of a variable size can be obtained, such as from 60 to 1,200 nm, preferably from 100 to 1,000 nm.
- the formulations containing the liposomes described above can be in various ways depending on the intended mode of administration.
- examples of such formulations are e.g. B. lyophilized compositions obtained by lyophilizing the above-described compositions suspended in a buffer, which lyophilisates can be further processed in various ways. Examples of such further processing are the introduction into a hard gelatin capsule, the shaping into a tablet, in particular into a tablet with an acid-resistant coating.
- the liposomes thus produced are particularly suitable for the transport of active substances based on peptides, these active substances preferably being peptides with a molecular weight in the range from 200 to 100,000 Da, such as parathyroid hormone, salmon calcitonin, GCSF, octreotide, hGH, insulin and the like.
- active substances which can be formulated with the compositions according to the invention to form liposomes containing active substance are octreotide, calcitonin, parathyroid hormone and somatropin.
- the active ingredients to be introduced into the liposomes can either be present originally in the composition according to the invention or can be formed the liposomes are added.
- the amount of active ingredient used in the respective formulations can of course vary depending on the intended use. However, it has been found that particularly stable and efficient liposomes containing active substance can be obtained if the ratio between the total molarity of lipid and tetraetheriipid to the mass of the active substance is in the range from 0.01 to 0.2 micromol / microgram, more preferably in the range from 0.03 micromol / microgram to 0.15 micromol / microgram, and most preferably between 0.05 micromol / microgram and 0.1 micromol / microgram.
- compositions of the invention enable the active ingredients to be available orally, which can also be controlled via the ratio of total lipid to active ingredient (preferably peptide active ingredient).
- active ingredients preferably peptide active ingredient.
- formulations formed from conventional lipids the above-mentioned values show that when the mixture of double layer-forming lipid and double layer-spanning tetraetheriipid is used according to the invention, less total lipid content is necessary in order to achieve good oral availability.
- the bioavailability of liposomally administered octreotides per os in rats is determined in a conventional manner, for example as described below.
- Wistar rats (with about 250 g body weight) fast for 12 hours and receive 0.5 mL of the aqueous mixture of the composition according to the invention by gavage, so that the amount of octreotide administered is 100 ⁇ g per animal.
- 100 ⁇ g free octreotide are dissolved in 0.5 mL PBS and administered by gavage.
- Blood samples are taken retroorbitally after 30, 60, 120, 240 min.
- An iv injection of 2 ⁇ g octreotide per animal serves as a control for the absolute bioavailability. to determine.
- An absolute bioavailability of 0.5% was measured for free octreotide.
- Six animals were tested for each formulation.
- Example 1 Oral administration of octreotide with liposomes with the composition of DSPC and GCTE, with a molar ratio of DSPC: GCTE of 3: 1 and a ratio of the molarity of the total lipid to the mass of the peptide of 0.097 ⁇ mol / ⁇ g and 0.038 ⁇ mol / ⁇ g and oral administration of octreotide with liposomes with the composition of DPPC and GCTE, with a molar ratio DPPC: GCTE of 3: 1 and a ratio of the molarity of the total lipid to the mass of the peptide of 0.013 ⁇ mol / ⁇ g and 0.029 ⁇ mol / ⁇ g.
- the respective reinforcement factors of absolute bioavailability and absolute bioavailability are shown in the following table:
- Example 2 Oral administration of octreotide with liposomes with the composition of DSPC and GCTE and AF1, with a molar ratio DSPC: GCTE: AF1 of 6: 1.5: 0.5 and a ratio of the molarity of the total lipid to the mass of the peptide of 0.081 ⁇ mol / ug.
- the gain factor of the absolute bioavailability of octreotide in this mixture compared to the absolute bioavailability of free octreotide is 12 and the absolute bioavailability is 6%.
- Example 3 Oral administration of octreotide with liposomes with the composition of DPPC and GCTE, with a molar ratio of DPPC.
- GCTE of 3 1 and a ratio of the molarity of the total lipid to the mass of the peptide of 0.013 ⁇ mol / ⁇ g; with a molar ratio DPPC.
- lipid to tetraetheriipid is in the lower range, preferably from 3: 1 to 2: 1, particularly preferably 2.5: 1.
- the lipid cholesterol and the tetraetheriipid are preferably a tetraetheriipid with a phosphatidylcholine head group ,
- a penetration enhancer to the liposome-forming composition.
- cholate derivative as the penetration enhancer, very preferred are chenodeoxycholic acid and ursodeoxycholic acid or mixtures of the two.
- the penetration enhancer in such a way that it is enclosed by the liposome together with the active ingredient and / or it is also preferred that the penetration enhancer is incorporated in the liposome membrane, which in turn encloses the active ingredient.
- peptides with a therapeutic daily dose of 10-100 ⁇ g / kg it is preferred to choose the mass ratio of penetration enhancer to peptide greater than 12.5 but less than 1000.
- peptides with a therapeutic daily dose of 10-100 ⁇ g / kg it is preferred for peptides with a therapeutic daily dose of 10-100 ⁇ g / kg to choose the mass ratio of peptide to liposomal envelope greater than 0.1 but less than 10.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003293621A AU2003293621A1 (en) | 2002-10-23 | 2003-10-23 | Liposome-forming compositions |
US10/532,576 US20060182792A1 (en) | 2002-10-23 | 2003-10-23 | Liposome-forming compositions |
EP03788961A EP1556005A2 (de) | 2002-10-23 | 2003-10-23 | Liposomen formende zusammensetzung |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10249401.0 | 2002-10-23 | ||
DE10249401A DE10249401A1 (de) | 2002-10-23 | 2002-10-23 | Liposomen formende Zusammensetzung |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004037223A2 true WO2004037223A2 (de) | 2004-05-06 |
WO2004037223A3 WO2004037223A3 (de) | 2004-06-24 |
Family
ID=32102907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/011758 WO2004037223A2 (de) | 2002-10-23 | 2003-10-23 | Liposomen formende zusammensetzung |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060182792A1 (de) |
EP (1) | EP1556005A2 (de) |
AU (1) | AU2003293621A1 (de) |
DE (1) | DE10249401A1 (de) |
WO (1) | WO2004037223A2 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2711369A1 (de) | 2012-09-20 | 2014-03-26 | Bernina Plus GmbH | Liposome mit Tetraetherlipidderivaten |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007005404A1 (en) | 2005-06-30 | 2007-01-11 | Wyeth | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION |
CA2523032A1 (en) | 2005-10-07 | 2007-04-07 | Immunovaccine Technologies Inc. | Vaccines for cancer therapy |
DE102007027850A1 (de) * | 2007-06-13 | 2008-12-24 | Beiersdorf Ag | Transparente kosmetische Formulierungen |
ES2588705T3 (es) | 2007-09-27 | 2016-11-04 | Immunovaccine Technologies Inc. | Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo |
EP2296696B1 (de) | 2008-06-05 | 2014-08-27 | ImmunoVaccine Technologies Inc. | Zusammensetzungen mit liposomen, einem antigen, einem polynucleotid und einem träger mit einer kontinuierlichen phase einer hydrophoben substanz |
SG11201401177WA (en) | 2011-10-06 | 2014-04-28 | Immunovaccine Technologies Inc | Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof |
BR112017015510A2 (pt) | 2015-01-20 | 2018-01-30 | Xoc Pharmaceuticals Inc | composto de fórmula estrutural (i), método de tratamento e/ou prevenção, método de agonização do receptor d2 em um indivíduo, método de antagonização do receptor d3 em um indivíduo, método de agonização do receptor 5-ht1d em um indivíduo, método de agonização do receptor 5-ht1a em um indivíduo, método de agonização seletiva do receptor 5-ht1d em vez do receptor 5-ht1b em um indivíduo, método de agonização seletiva do re-ceptor 5-ht2c em vez do receptor 5-ht2a ou 5-ht2b em um indivíduo, método de agonização do receptor 5-ht2c em um indivíduo, método de fornecimento de atividade antagonista funcional no receptor 5-ht2b ou receptor 5-ht7, e, método de fornecimento de atividade antagonista funcional nos receptores adrenérgicos em um indivíduo |
JP6856532B2 (ja) | 2015-01-20 | 2021-04-07 | エックスオーシー ファーマシューティカルズ インコーポレイテッドXoc Pharmaceuticals, Inc | エルゴリン化合物およびその使用 |
CN111132980A (zh) | 2017-06-01 | 2020-05-08 | Xoc制药股份有限公司 | 用于医学的麦角灵衍生物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19736592A1 (de) * | 1997-08-22 | 1999-02-25 | Syrinx Diagnostika Gmbh | Tetraetherlipidderivate und Tetraetherlipidderivate enthaltende Liposomen und Lipidagglomerate sowie deren Verwendung |
DE10065561A1 (de) * | 2000-12-28 | 2002-07-11 | Bernina Biosystems Gmbh | Tetraetherlipidderivate und Tetraetherlipidderivate enthaltende Liposomen und Lipidagglomerate sowie deren Verwendung |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19607722A1 (de) * | 1996-02-29 | 1997-09-04 | Freisleben H J Dr | Tetraetherlipide und diese enthaltende Liposomen sowie deren Verwendung |
US6316260B1 (en) * | 1997-08-22 | 2001-11-13 | Bernina Biosystems Gmbh | Tetraether lipid derivatives and liposomes and lipid agglomerates containing tetraether lipid derivatives, and use thereof |
DE10116197A1 (de) * | 2001-03-30 | 2002-10-17 | Bernina Biosystems Gmbh | Neue Methylprednisolonderivate mit therapeutischer Wirkung |
-
2002
- 2002-10-23 DE DE10249401A patent/DE10249401A1/de not_active Withdrawn
-
2003
- 2003-10-23 AU AU2003293621A patent/AU2003293621A1/en not_active Abandoned
- 2003-10-23 EP EP03788961A patent/EP1556005A2/de not_active Withdrawn
- 2003-10-23 US US10/532,576 patent/US20060182792A1/en not_active Abandoned
- 2003-10-23 WO PCT/EP2003/011758 patent/WO2004037223A2/de not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19736592A1 (de) * | 1997-08-22 | 1999-02-25 | Syrinx Diagnostika Gmbh | Tetraetherlipidderivate und Tetraetherlipidderivate enthaltende Liposomen und Lipidagglomerate sowie deren Verwendung |
DE10065561A1 (de) * | 2000-12-28 | 2002-07-11 | Bernina Biosystems Gmbh | Tetraetherlipidderivate und Tetraetherlipidderivate enthaltende Liposomen und Lipidagglomerate sowie deren Verwendung |
Non-Patent Citations (1)
Title |
---|
MILLER I R ET AL: "THERMOTROPIC PROPERTIES OF BIPOLAR LIPIDS OF SULFOLOBUS-SOLFATARICUS AND OF THEIR MIXTURES WITH DIPALMITOYLPHOSPHATIDYLCHOLINE" BIOPHYSICAL CHEMISTRY, Bd. 22, Nr. 1-2, 1985, Seiten 27-35, XP002276552 & ISSN: 0301-4622 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2711369A1 (de) | 2012-09-20 | 2014-03-26 | Bernina Plus GmbH | Liposome mit Tetraetherlipidderivaten |
Also Published As
Publication number | Publication date |
---|---|
EP1556005A2 (de) | 2005-07-27 |
AU2003293621A1 (en) | 2004-05-13 |
WO2004037223A3 (de) | 2004-06-24 |
DE10249401A1 (de) | 2004-05-13 |
US20060182792A1 (en) | 2006-08-17 |
AU2003293621A8 (en) | 2004-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69825495T2 (de) | Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo | |
Fang et al. | Enhancement of the transdermal delivery of catechins by liposomes incorporating anionic surfactants and ethanol | |
DE60132184T2 (de) | Auf lipiden basierende arzneistoffabgabesysteme gegen parasitäre infektionen | |
EP2405896B1 (de) | Glycerosomes und ihre verwendung in pharmazeutischen und kosmetischen zubereitungen zur topischen verabreichung | |
DE112010001765T5 (de) | Formulierungen zur Behandlung von Gewebetiefenschmerz | |
WO2004037223A2 (de) | Liposomen formende zusammensetzung | |
US20090324709A1 (en) | Liposomal formulations | |
JP2008512444A (ja) | 神経変性状態の治療のための、両親媒性弱塩基様テンパミンを含むリポソーム製剤 | |
EP1135193A1 (de) | Mittel zur tumortherapie auf liposomenbasis die tamoxifen enthalten | |
US20020058060A1 (en) | Liposome for incorporating large amounts of hydrophobic substances | |
JPH0761940B2 (ja) | 外皮用リポソ−ム製剤 | |
DE69813287T2 (de) | Lipidzusammensetzungen und deren verwendung | |
EA038899B1 (ru) | Везикулярные композиции | |
PL183104B1 (pl) | Kompozycja liposomowa i kompozycja farmaceutyczna | |
DE4110779A1 (de) | Liposomale formulierungen antimykotischer, antibakterieller und/oder antiphlogistischer arzneimittel fuer die lokale und vaginale anwendung | |
CN112022860A (zh) | 一种抗炎组合物、制备方法以及应用 | |
DE4132677C2 (de) | Flüchtige Inhalationsnarkotika enthaltende Liposomen, ihre Herstellung und Verwendung | |
DE112013002492T5 (de) | Vesikuläre Formulierungen, Verwendungen und Verfahren | |
DE112013002488T5 (de) | Vesikuläre Formulierungen, Kits und Verwendungen | |
EP0488142A1 (de) | Verfahren zur Verkapselung fester oder flüssiger, lipophiler Wirkstoffe zu diesen Wirkstoff enthaltenden Phospholipid-Liposomen sowie Arzneimittel diese Liposomen enthaltend | |
DE60127140T2 (de) | Amphotericin b enthaltende strukturierte emulsion | |
US20050013833A1 (en) | Composition based on lipid lamellar vesicles incorporating at least a dhea compound | |
WO2000009071A2 (en) | A novel liposomal formulation useful in treatment of cancer and other proliferation diseases | |
DE60123132T2 (de) | Liposomenformulierung mit clobetasol propionate | |
DE60222843T2 (de) | Hydrophobe Iodverbindung enthaltendes Liposom und dieses enthaltendes Röntgenkontrastmittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003788961 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003788961 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006182792 Country of ref document: US Ref document number: 10532576 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10532576 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |